Terms: = Kidney tumors AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Treatment
6 results:
1. Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma.
Lin H; Fu L; Li P; Zhu J; Xu Q; Wang Y; Mumin MA; Zhou X; Chen Y; Shu G; Yao G; Chen M; Lu J; Zhang L; Liu Y; Zhao Y; Bao J; Chen W; Luo J; Li X; Chen Z; Cao J
J Transl Med; 2023 May; 21(1):343. PubMed ID: 37221577
[TBL] [Abstract] [Full Text] [Related]
2. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Klencke BJ; Ro S; Donahue R; Kawashima J; Mesa R;
Lancet; 2023 Jan; 401(10373):269-280. PubMed ID: 36709073
[TBL] [Abstract] [Full Text] [Related]
3. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract] [Full Text] [Related]
4. JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism.
Wu KL; Miao H; Khan S
Am J Physiol Renal Physiol; 2007 Dec; 293(6):F1836-46. PubMed ID: 17898043
[TBL] [Abstract] [Full Text] [Related]
5. Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance.
Shang D; Liu Y; Ito N; Kamoto T; Ogawa O
Cancer Sci; 2007 Aug; 98(8):1259-64. PubMed ID: 17573897
[TBL] [Abstract] [Full Text] [Related]
6. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.
Dovhey SE; Ghosh NS; Wright KL
Cancer Res; 2000 Oct; 60(20):5789-96. PubMed ID: 11059775
[TBL] [Abstract] [Full Text] [Related]
